Skip to main content
Cellectis logo

Cellectis — Investor Relations & Filings

Ticker · ALCLS ISIN · FR0010425595 LEI · 5493000KKX5VQ37Q2W83 PA Manufacturing
Open in API
Filings indexed 1,315 across all filing types
Latest filing 2026-05-12 Foreign Filer Report
Country FR France
Listing PA ALCLS

About Cellectis

https://cellectis.com/en

Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.

Recent filings

Filing Released Lang Actions
6-K - Cellectis S.A. (0001627281) (Filer)
Foreign Filer Report
2026-05-12 English
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
Regulatory Filings Classification · 40% confidence The document is a corporate press release announcing upcoming clinical data presentations at a scientific conference. It does not contain financial results, regulatory forms, management changes, or a formal report. It is not itself an investor slide deck, report publication announcement, or earnings release. Therefore it falls into the fallback “Regulatory Filings” category for miscellaneous announcements that do not fit other specific filing types.
2026-05-12 English
Cellectis présentera des données cliniques sur lasmé-cel et éti-cel au congrès annuel de l’EHA 2026
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing planned presentations of clinical trial data at the European Hematology Association conference. It contains no financial statements, no shareholder votes, no regulatory filings beyond forward‐looking statements, and no report attachments. It does not match any specific financial or corporate filing category (e.g., 10-K, IR, ER, CAP, AGM materials, etc.) and is best categorized in the fallback “Regulatory Filings” as a general announcement (RNS).
2026-05-12 French
6-K - Cellectis S.A. (0001627281) (Filer)
Foreign Filer Report
2026-05-11 English
Cellectis publie ses résultats financiers du premier trimestre 2026
Earnings Release Classification · 90% confidence The document is a press release announcing Cellectis’s first quarter 2026 financial results, including key highlights on cash position, revenue, R&D expenses, and partnerships. It is an initial announcement of quarterly operating and financial performance rather than a full interim report containing detailed financial statements. This corresponds to the Earnings Release category. Q1 2026
2026-05-11 French
Cellectis Reports Financial Results for the First Quarter 2026
Interim / Quarterly Report Classification · 95% confidence The document is a detailed Q1 2026 financial report including actual financial statements (‘unaudited interim condensed statements of consolidated financial position’), discussion of income, expenses, cash runway, and IFRS IAS 34 reference. This is a substantive interim report, not merely an earnings press release (highlights only) or a report publication announcement. It falls squarely under Interim / Quarterly Report (IR). Q1 2026
2026-05-11 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.